Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Oct 13, 2026
Biodexa Pharmaceuticals filed Prospectus Supplement No. 5 to its F-1 resale prospectus covering 170,150 ordinary shares (3,403 ADSs), incorporating a Form 6-K from October 8, 2026. The 6-K announces an ADS ratio change from one ADS per 50 ordinary shares to one ADS per 400 ordinary shares, effective on or about October 26, 2026, with holders exchanging eight old ADSs for one new ADS via depositary JPMorgan Chase. The company notes the change has the same effect as a one-for-eight reverse ADS split; ordinary shares are unaffected.
Key figures
- New ads ratio
- 1 ADS represents 400 ordinary shares
- Old ads ratio
- 1 ADS represented 50 ordinary shares
- Last closing price
- $0.3832 (Oct 12, 2026)
- Reverse split ratio
- 1 ADS : 8 old ADSs
- Resale ads registered
- 3403
- Resale shares registered
- 170150
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.